无锡药明康德新药开发股份有限公司 证券代码：603259 证券简称：药明康德 公告编号：临 2025-035 关于 2025 年第二次以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/9 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 4 月 7 月 8 | 9 | 日~2025 | 年 | 日 | | 预计回购金额 | 10亿元~10亿元 | | | | | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | √为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 2,855,916股 | | | | | | 累计已回购股数占总股本比例 | 0.0989% | | | | | | 累计已回购金额 | 160,058,458.32元 | | | | | | 实际回购价 ...

Investment Rating - The investment rating for Pharmaron is Equal-weight [4] Core Insights - The industry view is considered Attractive, with a price target set at Rmb27.40, indicating a 3% upside from the current price of Rmb26.61 [4] - In 1Q25, Pharmaron reported revenue of Rmb3,099 million, reflecting a 16% year-over-year growth, aligning with the 2025 guidance of 10-15% growth [7] - The revenue streams from North America, EU, and China showed year-over-year growth of 16.8%, 26.6%, and 13.1%, respectively, contributing approximately 65%, 18%, and 15% to total revenue [2] - The customer base saw revenue from the top 20 pharmaceutical customers grow by 29% year-over-year, while other customers grew by 14% [2] - Adjusted non-IFRS net profit for 1Q25 was Rmb349 million, a 3.1% increase year-over-year, with softer growth attributed to depreciation and amortization costs from biologics capacity launch [7] Summary by Sections Financial Performance - 1Q25 revenue was Rmb3,099 million, up 16% year-over-year, consistent with the guidance for 2025 [7] - Net operating cash flow increased by 14.4% to Rmb853 million, with capital expenditures of Rmb556 million, up 11.4% year-over-year [2] Customer and Market Dynamics - Revenue from the top 20 pharma customers increased by 29% year-over-year, while other customers saw a 14% growth [2] - New order growth for both Lab services and CMC was over 10%, although it decelerated from over 20% in 2024 due to a higher order base in 1Q24 [7] Valuation Metrics - The company has a market capitalization of Rmb29,328.6 million and an enterprise value of Rmb33,234.4 million [4] - The projected EPS for the fiscal years ending in 2024, 2025, and 2026 are Rmb0.97, Rmb1.26, and Rmb1.00, respectively [4]

Core Viewpoint - The company held its 2024 annual general meeting and approved several key resolutions, including a share buyback plan and financial reports for the year [2][11]. Group 1: Meeting Details - The annual general meeting was held on April 29, 2025, at the Sheraton Hotel in Shanghai [2]. - All 12 current directors and 3 supervisors attended the meeting, along with the company secretary and CFO [3]. Group 2: Resolutions Passed - The following resolutions were approved: - 2024 Board of Directors' Work Report [4]. - 2024 Supervisory Board's Work Report [4]. - 2024 Financial Settlement Report [5]. - 2024 Profit Distribution Plan [5]. - Authorization for the Board to formulate a mid-term dividend plan [5]. - Special dividend plan for 2025 [5]. - External guarantee limit for 2025 [5]. - Reappointment of accounting firms for 2025 [5]. - Approval for foreign exchange hedging business limit for 2025 [5]. - Change of registered capital and amendments to the Articles of Association [6]. - Share buyback plan for A-shares [6][12]. - Approval of the 2025 H-share incentive trust plan [7]. - General authorization for the Board to issue debt financing instruments [8]. Group 3: Share Buyback Plan - The company plans to repurchase A-shares with a total fund of RMB 1 billion, estimating to buy back approximately 10,863,661 shares, which is about 0.38% of the total issued shares [12]. - The registered capital will decrease from RMB 2,887,992,582 to RMB 2,877,128,921 following the buyback [12]. Group 4: Debt Notification - The company notified creditors that they have 45 days from the announcement date to declare their debts and request repayment or guarantees [13]. - Specific documentation is required for debt declaration, including contracts and identification [14][15].

Core Viewpoint - In Q1 2025, the company's performance exceeded expectations with significant profit margin improvements, driven by the CRDMO service model and continuous capacity ramp-up, alongside ongoing optimization of production processes and efficiency [1][9]. Financial Performance - The company reported Q1 2025 revenue of 9.655 billion yuan, a year-on-year increase of 20.96% [2]. - Net profit attributable to shareholders reached 3.672 billion yuan, up 89.06% year-on-year [2]. - Non-IFRS adjusted net profit was 2.68 billion yuan, reflecting a 40.0% increase [2]. Order Growth and Business Segments - As of March 2025, the company had a strong order backlog of 52.33 billion yuan, a 47.1% year-on-year increase, indicating robust demand for high-quality services [3]. - Revenue from U.S. clients was 6.38 billion yuan, up 28.4% year-on-year, while European clients contributed 1.3 billion yuan, a 26.2% increase [3]. Chemical Business Performance - The chemical business generated revenue of 7.39 billion yuan in Q1 2025, a 32.9% increase, driven by growth in D&M and TIDES business segments [4]. - The adjusted non-IFRS gross margin for the chemical business was 47.5%, an increase of 4.2 percentage points [4]. New Molecule Development - The company successfully synthesized and delivered over 460,000 new compounds in the past 12 months, a 6% increase [5]. - The D&M business segment reported revenue of 3.85 billion yuan, a 13.8% year-on-year increase [5]. Testing and Biological Services - Testing business revenue was 1.29 billion yuan, a 4.0% decline, primarily due to price adjustments in the domestic market [6]. - The biological business generated revenue of 610 million yuan, an 8.2% increase, contributing to the overall CRDMO business model [7]. Profitability and Efficiency - The company's gross margin for Q1 2025 was 42.26%, an increase of 4.13 percentage points year-on-year, attributed to capacity release and efficiency improvements [8]. - Operating cash flow was 3.195 billion yuan, a 41.57% increase, driven by profit growth [8]. Future Outlook - The company expects continued growth in D&M and TIDES business segments, supported by the CRDMO service model and increasing global drug development demand [9]. - Revenue projections for 2025 to 2027 are 42.609 billion yuan, 48.518 billion yuan, and 55.038 billion yuan, with respective year-on-year growth rates of 8.6%, 13.9%, and 13.4% [10].

Summary of Key Points Core Viewpoint - WuXi AppTec experienced significant trading activity on April 30, with a total of 152,200 shares traded through block transactions, amounting to 9.2017 million yuan, at a price of 60.45 yuan per share, reflecting a premium of 2.16% over the closing price of the day [2]. Trading Activity - On April 30, there were 2 block trades for WuXi AppTec, totaling 152,200 shares and 9.2017 million yuan in transaction value [2]. - The stock's closing price on the same day was 59.17 yuan, which represented a decline of 2.12% [2]. - The daily turnover rate was 1.72%, with a total trading volume of 2.561 billion yuan and a net outflow of 246 million yuan in main funds [2]. - Over the past 5 days, the stock has increased by 5.25%, with a total net inflow of 72.5224 million yuan [2]. Financing and Ratings - The latest margin financing balance for WuXi AppTec is 3.906 billion yuan, which has decreased by 323 million yuan over the past 5 days, a decline of 7.63% [2]. - In terms of institutional ratings, 6 institutions provided ratings for the stock in the past 5 days, with Huatai Securities setting the highest target price at 93.30 yuan as of April 29 [2].

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec, indicating a potential return of over 15% in the next 12 months [19]. Core Insights - WuXi AppTec reported strong financial performance for Q1 2025, with revenue increasing by 21.0% year-on-year to RMB 9.65 billion, and adjusted non-IFRS net profit rising by 40.0% to RMB 2.68 billion [1][2]. - The TIDES business segment experienced significant growth, with revenue soaring by 187.6% to RMB 22.4 billion, driven by expanded capacity and contributions from oral GLP-1 projects [2]. - Despite ongoing macroeconomic uncertainties, management reaffirmed its annual performance guidance, expecting a revenue growth of 10-15% and an expansion in adjusted non-IFRS net profit margin [1][2]. Financial Summary - For FY25E, revenue is projected at RMB 42.97 billion, reflecting a year-on-year growth of 9.5%, while adjusted net profit is expected to reach RMB 11.61 billion, a growth of 9.7% [4][16]. - The company’s unfulfilled contract amount grew by 47.1% year-on-year to RMB 52.33 billion by the end of Q1 2025, indicating a solid foundation for future growth [1]. - The report also highlights a decrease in the P/E ratio from 16.5 in FY24A to 15.0 in FY25E, suggesting improved valuation attractiveness [4][16]. Shareholder Returns - WuXi AppTec's board proposed a series of shareholder return plans, including maintaining a 30% annual cash dividend payout ratio and a one-time special dividend of RMB 10 billion in 2025 [3]. - The total proposed dividend and buyback plan amounts to nearly RMB 60 billion, representing 62% of the net profit attributable to shareholders for 2024 [3]. Valuation - The target price has been adjusted from RMB 94.05 to RMB 77.22 based on DCF valuation, reflecting a downside risk of 27.7% from the current price of RMB 60.45 [5][6].

Group 1 - Goldman Sachs raised the target price for WuXi AppTec to HKD 74.9, up from HKD 70.9, maintaining a "Neutral" rating [1] - The company reported strong Q1 performance, and management has maintained its guidance for FY 2025, aligning with Goldman Sachs' expectations [1] - If the company continues its strong performance in the next 1-2 quarters, there is potential for an upward revision of guidance in the second half of the year [1] Group 2 - Goldman Sachs expects the TIDES business to grow by 65% this year, surpassing the official guidance of 60% [1] - The revenue forecasts for the TIDES business for 2025 to 2027 have been increased by 3.1%, 5%, and 5% respectively [1] - The profit forecasts for 2025 to 2027 have been raised by 7%, 3.5%, and 2.3% respectively, reflecting better-than-expected performance in TIDES and small molecule R&D and manufacturing [1]

Core Viewpoint - WuXi AppTec (药明康德) has reported significant growth in its Q1 2025 financial results, with revenue and net profit reaching historical highs, driven by increased production capacity and operational efficiency [2][4]. Financial Performance - In Q1 2025, WuXi AppTec achieved revenue of 96.55 billion yuan, a year-on-year increase of 20.96%, and net profit of 36.72 billion yuan, up 89.06% [2][4]. - The company’s ongoing business orders reached 523.3 billion yuan as of March 31, 2025, reflecting a 47.1% year-on-year growth [3][10]. Business Segments - The TIDES (oligonucleotide and peptide) business generated revenue of 22.4 billion yuan in Q1 2025, marking a substantial year-on-year increase of 187.6% [3][10]. - The chemical business reported revenue of 73.91 billion yuan, up 32.87% year-on-year, with over 460,000 new compounds synthesized and delivered in the past 12 months [9]. - The small molecule D&M (Development and Manufacturing) business achieved revenue of 38.5 billion yuan, a 13.8% increase year-on-year [9]. Operational Efficiency - WuXi AppTec has optimized production processes and operational efficiency, contributing to improved profitability [4][10]. - The company has successfully passed FDA inspections for its Changzhou and Taixing API bases, with plans to increase small molecule API reactor capacity to over 4,000 KL by the end of 2025 [9]. Future Outlook - WuXi AppTec maintains its annual guidance, expecting a revenue growth of 10% to 15% for its ongoing business in 2025 [11].

证券代码：603259 证券简称：药明康德 公告编号：临 2025-032 无锡药明康德新药开发股份有限公司 2024年年度股东大会、2025 年第一次 A 股类别股东会 议及 2025 年第一次 H 股类别股东会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 年年度股东大会 2024 | | | --- | --- | | 1、出席会议的股东和代理人人数 | 3,794 | | 其中：A 股股东人数 | 3,793 | | 股） 境外上市外资股股东人数（H | 1 | | 2、出席会议的股东所持有表决权的股份总数（股） | 1,202,669,172 | | 其中：A 股股东持有股份总数 | 1,014,650,572 | | 境外上市外资股股东持有股份总数（H 股） | 188,018,600 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 41.6702 | | 其中：A | 股股东持股 ...

同日，公司 2024 年年度股东大会审议通过《关于 2025 年以集中竞价交易方 式回购公司 A 股股份的议案》，同意公司采用集中竞价交易方式回购公司 A 股股 份，回购的股份将在回购完成之后全部予以注销并减少注册资本。本次拟回购 A 股股份的资金总额为人民币 10 亿元，若按回购价格上限人民币 92.05 元/股测算， 预计本次回购股份数量约为 10,863,661 股，约占公司于本公告日已发行总股本 （即 2,887,992,582 股）的 0.38%（具体回购股份的数量和占公司总股本的比例以 回购完毕或回购期限届满时实际回购的股份数量为准）。具体内容详见 2024 年年 度股东大会相关公告。 根据上述回购方案，以公司本公告日的总股本为基础且仅考虑回购注销前述 预 计 本 次 回 购 股 份 数 量 约 为 10,863,661 股 计 算 ， 本 公 司 的 注 册 资 本 由 1 2,887,992,582 元减少为 2,877,128, 921 元，本公司的股份总数由 2,887,992,582 股 减少为 2,877,128,921 股。最终公司总股本及注册资本的变动情况以回购实际情 况及对应的减 ...